TPM3 and non-small cell lung carcinoma: The FDA approved Entrectinib (Rozlytek, Gnentech Inc., South San Francisco, CA, USA) as a new Trk inhibitor for pediatric and adult solid tumors that have Trk, ROS proto-oncogene 1 (ROS1), and anaplastic lymphoma kinase (ALK) fusion proteins without a known acquired resistance mutation, and for tumors which are metastatic or for adults with metastatic NSCLC which are ROS1-positive.